(Q37854708)

24 August 2017

1 reference

title

Anaplastic thyroid cancer: a comprehensive review of novel therapy (English)

1 reference

anaplastic thyroid cancer

24 August 2017

1 reference

Stefan L Kojic

1

1 reference

PubMed ID

21417853

24 August 2017

Scott S Strugnell

series ordinal

2

1 reference

PubMed ID

21417853

24 August 2017

Sam M Wiseman

series ordinal

3

1 reference

24 August 2017

1 March 2011

1 reference

Expert Review of Anticancer Therapy

24 August 2017

1 reference

24 August 2017

11

1 reference

24 August 2017

3

1 reference

24 August 2017

387-402

1 reference

Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies

24 August 2017

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Targeting the ubiquitin-proteasome pathway in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

New trends in the treatment of undifferentiated carcinomas of the thyroid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Anaplastic thyroid cancer evolved from papillary carcinoma: demonstration of anaplastic transformation by means of the inter-simple sequence repeat polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Anaplastic transformation of thyroid cancer: review of clinical, pathologic, and molecular evidence provides new insights into disease biology and future therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Dedifferentiated thyroid cancer: a therapeutic challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Primary cell cultures from anaplastic thyroid cancer obtained by fine-needle aspiration used for chemosensitivity tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Phase II trial of sorafenib in advanced thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Poorly differentiated thyroid carcinoma: diagnostic features and controversial issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Molecular pathology of thyroid cancer: diagnostic and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

PLK1 inhibitors: setting the mitotic death trap.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

A mammalian protein targeted by G1-arresting rapamycin-receptor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Role of the novel mTOR inhibitor RAD001 (everolimus) in anaplastic thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Gefitinib (Iressa) potentiates the effect of ionizing radiation in thyroid cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Oncocytic, focally anaplastic, thyroid cancer responding to erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

A phase II study of gefitinib in patients with advanced thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Anaplastic thyroid cancer, tumorigenesis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Concurrent cetuximab and bevacizumab therapy in a murine orthotopic model of anaplastic thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Novel vascular targeting/disrupting agents: combretastatin A4 phosphate and related compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Early clinical studies of novel therapies for thyroid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Molecularly targeted therapies for thyroid cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Tumor lysis syndrome in a multiple myeloma treated with thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Insular and anaplastic carcinoma of the thyroid: a 45-year comparative study at a single institution and a review of the significance of p53 and p21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Molecular pathogenesis of thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Expression of Aurora kinases in human thyroid carcinoma cell lines and tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Dehydroxymethylepoxyquinomicin, a novel nuclear Factor-kappaB inhibitor, enhances antitumor activity of taxanes in anaplastic thyroid cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

The neutrophil gelatinase-associated lipocalin (NGAL), a NF-kappaB-regulated gene, is a survival factor for thyroid neoplastic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

A small-molecule triptolide suppresses angiogenesis and invasion of human anaplastic thyroid carcinoma cells via down-regulation of the nuclear factor-kappa B pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

R-roscovitine sensitizes anaplastic thyroid carcinoma cells to TRAIL-induced apoptosis via regulation of IKK/NF-kappaB pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Peroxisome proliferator-activated receptor gamma inhibits follicular and anaplastic thyroid carcinoma cells growth by upregulating p21Cip1/WAF1 gene in a Sp1-dependent manner.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

The high affinity peroxisome proliferator-activated receptor-gamma agonist RS5444 inhibits both initiation and progression of colon tumors in azoxymethane-treated mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Reactivation of suppressed RhoB is a critical step for the inhibition of anaplastic thyroid cancer growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Anti-tumour activity of CS-7017, a selective peroxisome proliferator-activated receptor gamma agonist of thiazolidinedione class, in human tumour xenografts and a syngeneic tumour implant model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Troglitazone, the peroxisome proliferator-activated receptor-gamma agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Effect of peroxisome proliferator-activated receptor gamma agonist, rosiglitazone, on dedifferentiated thyroid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

RAR and RXR modulation in cancer and metabolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Effect of all-trans retinoic acid on sodium/iodide symporter expression, radioiodine uptake and gene expression profiles in a human anaplastic thyroid carcinoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

The optimal use of bexarotene in cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

In vivo and microarray analysis of rexinoid-responsive anaplastic thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Retinoic acid for redifferentiation of thyroid cancer--does it hold its promise?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

A phase II study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Involvement of glyceraldehyde-3-phosphate dehydrogenase in tumor necrosis factor-related apoptosis-inducing ligand-mediated death of thyroid cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Targeting the ubiquitin-proteasome system for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Synergy of a herpes oncolytic virus and paclitaxel for anaplastic thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

ONYX-411, a conditionally replicative oncolytic adenovirus, induces cell death in anaplastic thyroid carcinoma cell lines and suppresses the growth of xenograft tumors in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Bevacizumab increases viral distribution in human anaplastic thyroid carcinoma xenografts and enhances the effects of E1A-defective adenovirus dl922-947.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Treatment of anaplastic thyroid carcinoma in vitro with a mutant vaccinia virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Oncolytic vaccinia virotherapy of anaplastic thyroid cancer in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Emerging molecular therapies of advanced thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Novel chemotherapy options for advanced thyroid tumors: small molecules offer great hope

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Treatment of recurrent thyroid cancers--is there a light in the horizon?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

New therapeutic advances in the management of progressive thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Next-generation DNA sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

The new paradigm of flow cell sequencing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Advances in cellular therapy for the treatment of thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Targeting epidermal growth factor receptor 1 signaling in human thyroid-stimulating hormone-independent thyroid carcinoma FRO cells results in a more chemosensitive and less angiogenic phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

Cancer Genomes on a Shoestring Budget

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.179

21 January 2018

Identifiers

DOI

10.1586/ERA.10.179

1 reference

24 August 2017

1 reference

PubMed ID

21417853